Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRETZCEL: Zr-89 crefmirlimab berdoxam PET Repeatability
NCT05744128Phase 2Terminated
- Sponsor
- ImaginAb
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of zirconium-89 crefmirlimab berdoxam in melanoma, renal cell carcinoma (RCC), sponsored by ImaginAb. Started Feb 2023; status: terminated.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05744128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744128.